ACTR-51. PHASE 2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND CLINICAL ACTIVITY OF PI3K/MTOR INHIBITOR GDC-0084 GIVEN TO GLIOBLASTOMA (GBM) PATIENTS WITH UNMETHYLATED O(6)-METHYLGUANINE-METHYLTRANSFERASE PROMOTER STATUS

BACKGROUND: GDC-0084 is a potent, oral, selective small molecule inhibitor of class I phosphoinositide 3-kinase and mammalian target of rapamycin (PI3K/mTOR) efficacious in GBM models driven by activation of the PI3K pathway. GDC-0084 crosses the blood-brain barrier (BBB) and achieves a brain / plas...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Wen, Patrick, Cloughesy, Timothy, de Groot, John, Battiste, James, Garner, James, Simpson, Jeremy, Olivero, Alan, Gerstner, Elizabeth
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216419/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.083
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados